

## WEST Search History


DATE : Tuesday, November 25, 2003

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
			result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR</i>			
L6	L2 and (valeramide or valerate or valeric)	7	L6
L5	L2 and (isovaleramide or isovalerate or isovaleric)	0	L5
L4	L2 and (isovelaramide or isovalerate or isovaleric)	0	L4
L3	L2 and (film or cellulose) adj3 coat\$5	19	L3
L2	L1 and (matrix or core) same (hydrogel or xanthan or gum or swelling or swellable or gel or gelling or gellant)	59	L2
L1	(anxiolytic or anxiolysis or sedative or hypnotic or tranquilizer or sedation) same (sustained or prolonged or controlled) adj3 release	288	L1

END OF SEARCH HISTORY

**WEST**[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#) | [Search Form](#) | [Pending Counts](#) | [Show S Numbers](#) | [Edit S Numbers](#) | [Preferences](#) | [Cases](#)**Search Results -**

Term	Documents
RELEASE	886574
RELEASES	177875
SUSTAINED	96570
SUSTAINEDS	0
PROLONGED	169964
PROLONGEDS	0
CONTINUOUS	1327338
CONTINUOU	54
(9 SAME (RELEASE ADJ3 (SUSTAINED OR PROLONGED OR CONTINUOUS))).USPT,PGPB,JPAB,EPAB,DWPI.	0
(L9 SAME RELEASE ADJ3 (SUSTAINED OR PROLONGED OR CONTINUOUS)).USPT,PGPB,JPAB,EPAB,DWPI.	0

**Database:** IBM Technical Disclosure Bulletins**Search:**

L13

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History****DATE:** Tuesday, November 25, 2003    [Printable Copy](#)    [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
	<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR</i>		
<u>L13</u>	L9 same release adj3 (sustained or prolonged or continuous)	0	<u>L13</u>
<u>L12</u>	L9 and release adj3 (sustained or prolonged or continuous) and (hydrogel or gelling or gum or polysaccharide or cellulose)	10	<u>L12</u>
<u>L11</u>	L9 and release adj3 (sustained or prolonged or continuous) and (core or matrix) same (hydrogel or gelling or gum or polysaccharide or cellulose)	1	<u>L11</u>
<u>L10</u>	L9 and 11	2	<u>L10</u>
<u>L9</u>	isovaleramide or isovaleric	2990	<u>L9</u>
<u>L8</u>	L7 and (anxiolytic or anxiety or hypnotic or sedative)	1	<u>L8</u>
<u>L7</u>	L1 and matrix same (hydrogel or gelling or gum or polysaccharide or cellulose)	10	<u>L7</u>
<u>L6</u>	L2 and (anxiolytic or anxiety or hypnotic or sedative)	0	<u>L6</u>
<u>L5</u>	L4 and (anxiolytic or anxiety or hypnotic or sedative)	0	<u>L5</u>
<u>L4</u>	L1 and core same (hydrogel or gelling or gum or polysaccharide or cellulose)	9	<u>L4</u>
<u>L3</u>	L1 and matrix same core same (hydrogel or gelling or gum or polysaccharide or cellulose)	0	<u>L3</u>
<u>L2</u>	L1 and matrix same core	19	<u>L2</u>
<u>L1</u>	release adj3 (sustained or prolonged or continuous) same (hydrophilic or water adj soluble ) adj5 (compound or active or drug or therapeutic or pharmaceutical)	106	<u>L1</u>

END OF SEARCH HISTORY

=> d his full

(FILE 'HOME' ENTERED AT 10:53:37 ON 25 NOV 2003)

FILE 'REGISTRY' ENTERED AT 10:53:49 ON 25 NOV 2003

E ISOVALERAMIDE/CN

L1 1 SEA ABB=ON PLU=ON ISOVALERAMIDE/CN

D L1

L2 1 SEA ABB=ON PLU=ON ISOVALERATE/CN

D L2

L3 1 SEA ABB=ON PLU=ON "ISOVALERIC ACID"/CN

D L3

FILE 'CAPLUS' ENTERED AT 10:55:44 ON 25 NOV 2003

L4 7 SEA ABB=ON PLU=ON (L1 OR L2 OR L3) AND (SUSTAINED OR PROLONGED OR CONTROLLED) (2A) RELEASE

D L4 IBIB KWIC 1-

L5 19 SEA ABB=ON PLU=ON (L1 OR L2 OR L3) AND (TABLET OR CAPSULE OR DOSAGE FORM)

L6 0 SEA ABB=ON PLU=ON L5 AND (MATRIX OR CORE) (P) (GELLING OR GELLANT OR GUM OR POLYSACCHARIDE OR HYDROGEL)

L7 2 SEA ABB=ON PLU=ON L5 AND (SWELLING OR SWELLABLE OR GELLING OR GELLANT OR GUM OR POLYSACCHARIDE OR HYDROGEL)

D L7 IBIB KWIC 1-

D L5 IBIB KWIC 1-

L8 743 SEA ABB=ON PLU=ON (TABLET OR CAPSULE OR DOSAGE FORM) (P) (SUSTAINED OR PROLONGED) (3A) RELEASE AND (SWELLING OR SWELLABLE OR GELLING OR GELLANT OR GUM OR POLYSACCHARIDE OR HYDROGEL)

L9 244 SEA ABB=ON PLU=ON (TABLET OR CAPSULE OR DOSAGE FORM) (P) (SUSTAINED OR PROLONGED) (3A) RELEASE AND (CORE OR MATRIX) (P) (SWELLING OR SWELLABLE OR GELLING OR GELLANT OR GUM OR POLYSACCHARIDE OR HYDROGEL)

L10 10 SEA ABB=ON PLU=ON L9 AND (FILM OR RETARDANT) (3A) COAT?

L11 1 SEA ABB=ON PLU=ON L10 AND (ANXIETY OR ANXIOLYTIC OR SEDATIVE OR HYPNOTIC OR CNS DISORDER)

D L11 IBIB KWIC

L12 1 SEA ABB=ON PLU=ON L10 AND (ANXIETY OR ANXIOLYTIC OR SEDATIVE OR HYPNOTIC OR CNS DISORDER)

D L10 IBIB KWIC 1-

L5 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 1993:132151 CAPLUS  
 DOCUMENT NUMBER: 118:132151  
 TITLE: Therapeutic nutrients containing glycerides of branched chain fatty acids  
 INVENTOR(S): Sommermeyer, Klaus  
 PATENT ASSIGNEE(S): Fresenius A.-G., Germany  
 SOURCE: Ger. Offen., 6 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4116004	A1	19921119	DE 1991-4116004	19910516
DE 4116004	C2	19930930		
WO 9220241	A1	19921126	WO 1992-EP1049	19920513
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
EP 584159	A1	19940302	EP 1992-910171	19920513
EP 584159	B1	19951227		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 06511384	T2	19941222	JP 1992-509184	19920513
AT 132012	E	19960115	AT 1992-910171	19920513
ES 2081108	T3	19960216	ES 1992-910171	19920513
US 5492713	A	19960220	US 1994-150039	19940805
PRIORITY APPLN. INFO.:			DE 1991-4116004	19910516
			WO 1992-EP1049	19920513

OTHER SOURCE(S): MARPAT 118:132151

AB Glycerides contg. branched fatty acids,  $\text{MeRCH}(\text{CH}_2)^m(\text{CH}_2)^n\text{CO}_2\text{H}$  ( $\text{R} = \text{Me, Et}$ ;  $n = 0$  or even no. from 2-18;  $m = 0,1$ ) are used in therapeutic diets for treatment of trauma and sepsis, esp. uremia. These may be used in oral or parenteral formulations. These fatty acids act as a source of branched-chain keto-acids for use in branched chain amino acid biosynthesis to maintain protein synthesis in the liver. The prepn. of glyceryl triisovalerate, glyceryl tri-(3-methylvalerate), and glyceryl tri-(4-methylvalerate) by acid-catalyzed esterification is demonstrated. Formulations and **dosage forms (capsules)** using these glycerides are described.

- IT Pharmaceutical **dosage forms**  
(**capsules**, contg. glycerides of branched-chain fatty acids, for treatment of uremia)
- IT Pharmaceutical **dosage forms**  
(emulsions, contg. glycerides of branched-chain fatty acids, for treatment of uremia)
- IT 105-43-1, 3-Methylvaleric acid **503-74-2**, Isovaleric acid  
646-07-1, 4-Methylvaleric acid  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of, in prepn. of glycerides for therapeutic nutrients for treatment of uremia)

L5 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN  
ACCESSION NUMBER: 1991:506014 CAPLUS  
DOCUMENT NUMBER: 115:106014  
TITLE: Short-chain fatty acids for treating inflammatory bowel disorders  
INVENTOR(S): Breuer, Richard I.  
PATENT ASSIGNEE(S): USA  
SOURCE: PCT Int. Appl., 19 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9107176	A1	19910530	WO 1990-US6697	19901115
W: CA, FI, JP, NO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
US 5039703	A	19910813	US 1989-438297	19891116
CA 2071215	AA	19910517	CA 1990-2071215	19901115
CA 2071215	C	19970204		
EP 502925	A1	19920916	EP 1991-900102	19901115
EP 502925	B1	19960925		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 143261	E	19961015	AT 1991-900102	19901115
ES 2093695	T3	19970101	ES 1991-900102	19901115
IL 96365	A1	19950629	IL 1990-96365	19901116
AU 9066817	A1	19910523	AU 1990-66817	19901121
AU 9350516	A1	19940113	AU 1993-50516	19931108
AU 664492	B2	19951116		
PRIORITY APPLN. INFO.:			US 1989-438297	19891116
			WO 1990-US6697	19901115
IT Pharmaceutical dosage forms				
				(enemas, short-chain fatty acids in, for colon inflammation treatment)
IT 64-19-7, Acetic acid, biological studies			79-09-4, Propanoic acid,	
biological studies			79-31-2, Isobutyric acid	107-92-6, Butyric acid,
biological studies			109-52-4, Valeric acid, biological studies	
503-74-2, Isovaleric acid			135852-25-4	
RL: BIOL (Biological study)				(colon inflammation treatment with)